Vadimezan is safe and active in both squamous and non-squamous NSCLCAn abstract is unavailable.doi:10.1097/01.OTU.0000398562.48570.81TumaRabiya SOncology Times Uk
Nonsquamous Disease Treating Squamous vs Nonsquamous DiseaseTreating Squamous vs Nonsquamous DiseaseCheryl Zigrand
For example,bevacizumabis contraindicated in patients withsquamous cell lung cancer, because of an increased risk of fatalhemoptysis.3,4Pemetrexedis approved for the treatment of nonsquamous NSCLC only, as multiple studies have shown greater efficacy in nonsquamous as compared to squamous cancers.5–...
(B) Non-squamous NSCLC (LAC and LCC; P ¼ 0.878; log rank); (C) early UICC stages I and II including the whole cohort (P ¼ 0.009; log rank); (D) advanced UICC stages III and IV including the whole cohort (P ¼ 0.903; log rank); (E) early UICC stages I and II in ...
different patient populations but similar enough. How are these 3 trials impacting what you’re thinking about in those patients who are less than 50%-positive but also in those patients with a high PD-L1 [programmed cell death ligand 1] score with nonsquamous non–small cell lung cancer?
Non-squamous NSCLC cases with EGFR-sensitizing mutations were treated with anlotinib and icotinib. The primary endpoint was progression-free survival (PFS). Secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity. Results Sixty...
Outside of HNSCC, attempts to understand cancer-specific states of exhaustion have been used in melanoma [72,73,96] and non-small cell lung cancer (NSCLC). Guo et al. utilized deep scRNA-seq to identify two novel clusters of T cells exhibiting states appearing to precede exhaustion ...
A Phase III study comparing tusamitamab ravtansine with docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and immunotherapy (in combination or sequential), whose tumors
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer Atezolizumab, nivolumab, and pembrolizumab increase overall survival in second-line treatment of Stage III/IV squamous and non-squamous NSCLC when compared to.....
Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC),NHMRC Clinical Trials Centre,Interventional,Phase 2